HORBÄACH - WOMEN'S 50+ MULTIVITAMINS & MINERALS
Food supplement declared in France, decision dated 9 December 2024
HORBÄACH - WOMEN'S 50+ MULTIVITAMINS & MINERALS, from PIPING ROCK UK LIMITED, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: isoflavones 15 mg per day, lutéine 1 mg per day, Vaccinium macrocarpon 2 mg per day, Pantothenic acid (vitamin B5), Biotin (vitamin B8). None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.
- Brand
- not provided
- Food business operator placing the product on the market
- PIPING ROCK UK LIMITED
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Tablet
- Daily dose
- 2 comprimés par jour
- Intended populations
- Women
- Not recommended (according to the manufacturer)
- Adolescents (moins de 18 ans), Antécédent de cancer du sein, Autre : Energie et Métabolisme, Femmes enceintes, Sous anticoagulants, Sous traitement pour la thyroïde, Utilisation prolongée
- Objectives stated by the manufacturer (these are not authorised claims)
- Autre : Energie et Métabolisme, Cheveux et ongles, Immunité, Os, Peau
Declaration 1796, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Vaccinium macrocarpon Aiton | Fruit | Extrait sec hydroalcoolique | 2 mg |
Substances
| Name | Per day |
|---|---|
| isoflavones | 15 mg |
| lutéine | 1 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Ubiquinone | not declared |
| Citroflavonoïdes | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-pantothenate, calcium | Pantothenic acid (vitamin B5) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| D-biotin | Biotin (vitamin B8) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| calcium salts of orthophosphoric acid | Calcium | 2,500 mg | 800 mg |
| chromium picolinate | Chromium | no limit (insufficient data) | 25 µg |
| cupric gluconate | Copper | 5,000 µg | 2,000 µg |
| ferrous bisglycinate | Iron | 40 mg (safe level) | 14 mg |
| pteroylmonoglutamic acid | Folate (vitamin B9) | 1,000 µg | 200 µg |
| potassium iodide | Iodine | 600 µg | 150 µg |
| magnesium oxide | Magnesium | 250 mg | 300 mg |
| manganese sulphate | Manganese | 8 mg (safe level) | 3.5 mg |
| nicotinamide | Nicotinamide (vitamin B3) | 900 mg | 54 mg |
| sodium selenite | Selenium | 255 µg | 50 µg |
| retinyl acetate | Vitamin A | 3,000 µg d'équivalent rétinol | 800 µg |
| thiamin hydrochloride | Vitamin B1 (thiamine) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| cyanocobalamin | Vitamin B12 | no adverse effect defined | dose annulled by the French Council of State in 2011 |
| riboflavin | Vitamin B2 (riboflavin) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| pyridoxine hydrochloride | Vitamin B6 | 12 mg | 2 mg |
| L-ascorbic acid | Vitamin C | no limit (insufficient data) | 180 mg |
| cholecalciferol | Vitamin D | 100 µg (4,000 IU) | 5 µg (200 IU) |
| D-alpha-tocopheryl acid succinate | Vitamin E | 300 mg | 30 mg |
| menaquinone | Vitamin K | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| zinc oxide | Zinc | 25 mg | 15 mg |
Additives
E170, E412, E464, E1200, E551, E470b, E460
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Ne pas dépasser la dose journalière recommandée. Les compléments alimentaires ne doivent pas être utilisés comme substituts d'un régime alimentaire varié et équilibré et d'un mode de vie sain. Tenir hors de la portée des jeunes enfants. Si vous allaitez, si vous prenez des médicaments ou si vous avez des réactions inattendues, consultez votre médecin. Déconseillé aux personnes souffrant de maladies ayant pour conséquence une accumulation anormale de fer, aux femmes enceintes ou désireuses de l’être, ainsi qu’aux femmes ménopausées. Déconseillé aux personnes souffrant de troubles de la thyroïde et aux personnes sous traitement anticoagulant. Usage prolongé déconseillé. Déconseille aux femmes ayants des antécédents personnels ou familiaux de cancer du sein. Réservé à l'adulte. Ne pas utiliser si le sceau est cassé.
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Vaccinium macrocarpon Aiton
Read the warning, when it applies and the studies cited
CRANBERRY - VACCINIUM MACROCARPON
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
Sources cited by Health Canada (2)
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
- Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
Sources cited by Health Canada (4)
- Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
- Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.
Condition of application: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
DRIED CRANBERRY JUICE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
Sources cited by Health Canada (2)
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
- Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
Sources cited by Health Canada (4)
- Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
- Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.
Condition of application: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Ubiquinone
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- HORBÄACH - WOMEN'S 50+ MULTIVITAMINS & MINERALS PIPING ROCK UK LIMITED, declared in 2025 : different composition: 11 ingredient(s) added, 10 missing
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “HORBÄACH - WOMEN'S 50+ MULTIVITAMINS & MINERALS: composition and regulation”, https://compoatlas.com/en/supplements/products/1796-horbaach-women-s-50-multivitamins-minerals, updated 15 November 2026.